Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Caliper Posts Decreased Revenue, Widened Losses in Q1

SAN FRANCISCO, May 7 - Caliper Technologies today reported decreased revenues for the first quarter.

 

Total revenue for the quarter ended March 31 was $7 million compared with $9.8 million in the year-ago period.

 

Last year's first quarter revenue included a $5 million licensing fee from Aclara BioSciences as part of a litigation statement, Caliper said.

 

The net loss for the quarter was $9.7 million, or $.40 per share, compared to an income of $26.4 million, or $1.03 a share, for the same period a year ago. Included in 2001 first quarter income was a $27.5 million settlement from Aclara BioSciences. Excluding that payment, net loss for the first quarter of 2001 was $1.1 million, or $.05 a share, according to the company.

R&D spending for the quarter rose to approximately $11 million from $8.8 million for the year-ago period. 

 

The company said it had $151.3 million in cash, cash equivalents, and short-term marketable securities as of March 31.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.